The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Ming Chen
No Relationships to Disclose
 
Qing Zhou
No Relationships to Disclose
 
Hao Li
Employment - CStone Pharmaceuticals
 
Wenyi Sun
Employment - CStone Pharmaceuticals
 
Hongyan He
Employment - CStone Pharmaceuticals
 
Dongmei Lu
Employment - Bayer; CStone Pharmaceuticals